Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Human Growth Hormone Market Size, Value And Growth Trajectory Through 2030
The human growth hormone market has experienced robust expansion over the past few years. Its valuation is projected to increase from $5.18 billion in 2025 to reach $5.68 billion by 2026, demonstrating a compound annual growth rate (CAGR) of 9.5%. Historically, this expansion has been driven by several factors, including a rise in the diagnosis of growth hormone deficiency, an increase in the production of recombinant hormones, heightened public awareness concerning pediatric growth disorders, the greater accessibility of branded HGH therapies, and the established clinical application of hormone replacement.
The market for human growth hormone is anticipated to experience substantial expansion in the coming years. Projections indicate it will reach $7.87 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 8.5%. This anticipated growth during the forecast timeframe is attributable to several factors, including the escalating demand for long-acting growth hormone treatments, the increasing incidence of adult growth hormone deficiency, an intensified focus on customized endocrine therapies, the broadening reach of specialty pharmacy distribution channels, and greater investment in hormone therapy research. Key trends anticipated within this period encompass a heightened demand for treatments addressing growth hormone deficiency, the rising acceptance of long-acting growth hormone formulations, expanded application of HGH in pediatric endocrinology, the proliferation of recombinant growth hormone therapies, and an enhanced emphasis on patient compliance and ease of administration.
Get A Free Sample Report With In-Depth Market Insights:
Human Growth Hormone Market Industry Drivers: What’s Behind The Revenue Growth?
The expansion of the aging population is anticipated to fuel the growth of the human growth hormone market in the future. An aging population is characterized by an increasing share of older individuals within a society, a trend resulting from longer life expectancies and reduced birth rates. This demographic shift is accelerating due to healthcare innovations that have extended human lifespan. The aging demographic utilizes human growth hormone, under medical guidance, to combat age-associated issues such as muscle loss, diminished energy levels, and metabolic deterioration. For example, the Population Reference Bureau, a US-based non-profit, indicated in January 2024 that the population of Americans aged 65 and above is projected to increase from 58 million in 2022 to 82 million by 2050, representing a 47% growth. Consequently, this cohort’s share of the overall U.S. population will expand from 17% to 23% within this timeframe. Therefore, the expanding aging population is a key driver for the human growth hormone market.
Human Growth Hormone Market Segmentation And Category Overview
The human growth hormone market covered in this report is segmented –
1) By Product: Liquid, Powder
2) By Brand: Norditropin, Genotropin, Humatrope, Saizen, Omnitrope, Skytrofa, Other Brands
3) By Route Of Administration: Intramuscular, Subcutaneous
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacy, Specialty Pharmacy
5) By Application: Growth Hormone (GH) Deficiency, Adult Growth Hormone (GH) Deficiency, Pediatric Growth Hormone (GH) Deficiency, Turner Syndrome, Idiopathic Short Stature, Prader-Willi Syndrome, Small For Gestational Age, Other Applications
Subsegments:
1) By Liquid: Pre-Filled Liquid Syringes, Vials Of Liquid Growth Hormone
2) By Powder: Reconstitutable Powder, Freeze-Dried Powder
#Human Growth Hormone Market Growth Trends: What’s Shaping The Future Outlook?
Key players in the human growth hormone market are increasingly prioritizing drug development and securing approvals to innovate their medication offerings and deliver enhanced treatment solutions. The process of drug development is intricate and stringent, involving multiple stages to guarantee a new drug’s safety, efficacy, and quality before its introduction to the market. For example, in June 2023, Pfizer Inc., a US-based biopharmaceutical company, and OPKO Health Inc., a US-based biopharmaceutical and diagnostics company, reported that NGENLA (somatrogon-ghla) had received approval from the Food and Drug Administration (FDA). This therapy offers a more convenient dosing regimen and improves patient adherence when contrasted with daily injections. It allows children with growth hormone deficiency the choice to reduce injection frequency from daily to just once a week. The FDA approval was substantiated by a Phase 3 study that illustrated NGENLA’s non-inferiority compared to once-daily somatropin, exhibiting a safety profile consistent with somatropin.
Human Growth Hormone Market Competitive Analysis Of Leading Industry Participants
Major companies operating in the human growth hormone market are Pfizer Inc., Roche Holding AG, Novartis AG, Thermo Fisher Scientific Inc., Eli Lilly and Company, Novo Nordisk A/S, Merck KGaA, Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, Ipsen Pharma, Ferring Holding SA, Endo International, Zydus Lifesciences Limited, Opko Health, LG Life Sciences, EMD Serono Inc., Wockhardt Ltd., JCR Pharmaceuticals Co. Ltd., Genentech Inc., SOFAR S.p.A., United Laboratories, Ascendis Pharma, Uni-Pharma S.A., Versartis Inc., Reliance Life Sciences, Anhui Anke Biotechnology (Group) Co. Ltd., Rani Therapeutics
View The Full Human Growth Hormone Market Report:
Human Growth Hormone Market Geographic Spread And Regional Opportunities
North America was the largest region in the human growth hormone market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the human growth hormone market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
